Foreign Currency Transaction Gain (Loss)
Vertex Pharmaceuticals Foreign Currency Transaction Gain (Loss) remained flat by 0.0% to -$3.43M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 49.8%, from -$6.83M to -$3.43M. Over 2 years (FY 2023 to FY 2025), Foreign Currency Transaction Gain (Loss) shows an upward trend with a -25.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A gain indicates favorable currency movements, while a loss indicates negative impact from currency volatility on international operations.
Detailed definition
This metric captures the realized and unrealized gains or losses arising from transactions denominated in currencies oth...
Peer comparison
Commonly reported by multinational corporations with significant cross-border trade.
abbv_foreign_currency_transaction_gain_lossHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$24.60M | -$27.30M | -$13.70M |
| YoY Change | — | -11.0% | +49.8% |
Foreign Currency Transaction Gain (Loss) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's foreign currency transaction gain (loss)?
- Vertex Pharmaceuticals (VRTX) reported foreign currency transaction gain (loss) of -$3.43M in Q4 2025.
- How has Vertex Pharmaceuticals's foreign currency transaction gain (loss) changed year-over-year?
- Vertex Pharmaceuticals's foreign currency transaction gain (loss) increased by 49.8% year-over-year, from -$6.83M to -$3.43M.
- What is the long-term trend for Vertex Pharmaceuticals's foreign currency transaction gain (loss)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's foreign currency transaction gain (loss) has grown at a -25.4% compound annual growth rate (CAGR), from -$24.60M to -$13.70M.
- What does foreign currency transaction gain (loss) mean?
- Profit or loss resulting from changes in currency values during international business transactions.